AU2016303662A1 - Bacteria engineered to treat disorders involving propionate catabolism - Google Patents

Bacteria engineered to treat disorders involving propionate catabolism Download PDF

Info

Publication number
AU2016303662A1
AU2016303662A1 AU2016303662A AU2016303662A AU2016303662A1 AU 2016303662 A1 AU2016303662 A1 AU 2016303662A1 AU 2016303662 A AU2016303662 A AU 2016303662A AU 2016303662 A AU2016303662 A AU 2016303662A AU 2016303662 A1 AU2016303662 A1 AU 2016303662A1
Authority
AU
Australia
Prior art keywords
gene
propionate
pct
bacterium
encoding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2016303662A
Other languages
English (en)
Inventor
Dean Falb
Vincent ISABELLA
Jonathan Kotula
Paul Miller
Yves Millet
Alex TUCKER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synlogic Operating Co Inc
Original Assignee
Synlogic Operating Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2016/032565 external-priority patent/WO2016183532A1/en
Priority claimed from PCT/US2016/037098 external-priority patent/WO2016201380A1/en
Application filed by Synlogic Operating Co Inc filed Critical Synlogic Operating Co Inc
Publication of AU2016303662A1 publication Critical patent/AU2016303662A1/en
Assigned to SYNLOGIC OPERATING COMPANY, INC. reassignment SYNLOGIC OPERATING COMPANY, INC. Alteration of Name(s) of Applicant(s) under S113 Assignors: SYNLOGIC, INC.
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
AU2016303662A 2015-07-31 2016-07-29 Bacteria engineered to treat disorders involving propionate catabolism Abandoned AU2016303662A1 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201562199445P 2015-07-31 2015-07-31
US62/199,445 2015-07-31
US201662336338P 2016-05-13 2016-05-13
PCT/US2016/032565 WO2016183532A1 (en) 2015-05-13 2016-05-13 Bacteria engineered to treat a disease or disorder
US62/336,338 2016-05-13
AUPCT/US2016/032565 2016-05-13
US201662341320P 2016-05-25 2016-05-25
US62/341,320 2016-05-25
PCT/US2016/037098 WO2016201380A1 (en) 2015-06-10 2016-06-10 Bacteria engineered to treat disorders involving the catabolism of a branched chain amino acid
AUPCT/US2016/037098 2016-06-10
PCT/US2016/044922 WO2017023818A1 (en) 2015-07-31 2016-07-29 Bacteria engineered to treat disorders involving propionate catabolism

Publications (1)

Publication Number Publication Date
AU2016303662A1 true AU2016303662A1 (en) 2018-02-22

Family

ID=57944027

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016303662A Abandoned AU2016303662A1 (en) 2015-07-31 2016-07-29 Bacteria engineered to treat disorders involving propionate catabolism

Country Status (5)

Country Link
EP (1) EP3328988A1 (cg-RX-API-DMAC7.html)
JP (1) JP2018521674A (cg-RX-API-DMAC7.html)
AU (1) AU2016303662A1 (cg-RX-API-DMAC7.html)
CA (1) CA2996535A1 (cg-RX-API-DMAC7.html)
WO (1) WO2017023818A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020005875A (es) 2017-12-05 2020-10-08 Bioplx Inc Métodos y composiciones para prevenir la infección microbiana.
CA3142608A1 (en) 2019-06-04 2020-12-10 Cocoon Biotech Inc. Silk-based products, formulations, and methods of use
CN112143689B (zh) * 2019-06-28 2023-01-03 中国科学院微生物研究所 重组恶臭假单胞菌株的构建及其在转化苏氨酸合成丙酸中的应用
WO2021137937A2 (en) * 2019-11-05 2021-07-08 The Trustees Of Columbia University In The City Of New York Engineered bacteria containing biosensors for precision targeting and containment
KR20220119030A (ko) 2019-12-02 2022-08-26 아스텔라스세이야쿠 가부시키가이샤 암의 처치에 이용하는 ny-eso-1 함유 인공 아주반트 벡터 세포
JP2023511305A (ja) * 2020-01-17 2023-03-17 ウニベルシテ カソリーク デ ルーベン 変化したエンベロープ完全性を有する遺伝子組換え細菌およびその使用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9107305D0 (en) 1991-04-08 1991-05-22 Unilever Plc Probiotic
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6203797B1 (en) 1998-01-06 2001-03-20 Stephen C. Perry Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome
CA2353800A1 (en) 1998-12-02 2000-06-08 Trustees Of Boston University Gene networks for control of gene expression
EP1034787A1 (en) 1999-03-11 2000-09-13 Société des Produits Nestlé S.A. Lactobacillus strains preventing diarrhea caused by pathogenic bacteria
US7731976B2 (en) 2003-08-29 2010-06-08 Cobb And Company, Llp Treatment of irritable bowel syndrome using probiotic composition
JP2014525266A (ja) * 2011-08-26 2014-09-29 マイクロバイオータ ダイアグノスティクス, エルエルシー 心欠陥を診断および治療する方法
EP2914274A4 (en) * 2012-11-01 2016-07-20 Sydney Children S Hospital Network Randwick And Westmead GENETICALLY MODIFIED PROBIOTIC FOR THE TREATMENT OF PHENYLKETONURIA
US9951340B2 (en) 2013-03-07 2018-04-24 The General Hospital Corporation Compositions and methods for bacterial delivery of polypeptides

Also Published As

Publication number Publication date
JP2018521674A (ja) 2018-08-09
CA2996535A1 (en) 2017-02-09
EP3328988A1 (en) 2018-06-06
WO2017023818A1 (en) 2017-02-09

Similar Documents

Publication Publication Date Title
US12409195B2 (en) Bacteria engineered to reduce hyperphenylalaninemia
US11845964B2 (en) Bacteria engineered to treat diseases associated with hyperammonemia
US20220233609A1 (en) Bacteria engineered to treat disorders in which oxalate is detrimental
EP3307870B1 (en) Bacteria engineered to treat disorders involving the catabolism of a branched chain amino acid
US20170216370A1 (en) Bacteria engineered to treat disorders involving propionate catabolism
US20170067065A1 (en) Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
US20230092431A1 (en) Bacteria engineered to treat disorders in which oxalate is detrimental
WO2017123592A1 (en) Bacteria engineered to treat disorders associated with bile salts
JP2018523978A (ja) 高アンモニア血症に関連する疾患を治療するために操作された細菌
WO2017075485A1 (en) Bacteria engineered to treat disorders in which trimethylamine (tma) is detrimental
EP3328988A1 (en) Bacteria engineered to treat disorders involving propionate catabolism
US20220168362A1 (en) Bacteria engineered to treat disorders involving the catabolism of a branched chain amino acid

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: SYNLOGIC OPERATING COMPANY, INC.

Free format text: FORMER NAME(S): SYNLOGIC, INC.

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application